OPKO Health, Inc.

$1.44 ▼ -1.37%
2026-06-06 09:49:01

Explore OPKO Health, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.

Market Cap
$1.09 B
Current Price
$1.44
52W High / Low
$1.6 / $0.98
Stock P/E
Book Value
$1.67
Dividend Yield
ROCE
-12.27%
ROE
-16.71%
Face Value
EPS
$-0.27
Exp Qtr EPS
Sector
Healthcare

OPK — Monthly Price History

Adjusted close price  ·  Hover to see price & month

Pros

  • Balance sheet leverage appears manageable.
  • Short-term liquidity looks comfortable.
  • Valuation is not stretched on P/E basis.

Cons

  • Return on equity is on the weaker side.
  • Capital efficiency is modest.
  • Operating margin is thin.
  • Net margin is relatively low.

Sift Stocks

S.No. Name Price P.E. Market Cap Div Yld % ROCE ROE 52Week High/ Low Book Value
1. Thermo Fisher Scientific Inc. $472.8 25.75 $176.31 B 0.39% 8.52% 13.24% $643.99 / $385.46 $141.96
2. Danaher Corporation $184.3 35.52 $131.02 B 0.86% 6.12% 7.06% $242.8 / $160.93 $74.32
3. IDEXX Laboratories, Inc. $562.16 40.5 $44.36 B 61.76% 70.87% $769.98 / $506.91 $20.14
4. Agilent Technologies, Inc. $135.44 27.28 $38.58 B 0.74% 14.25% 20.84% $160.27 / $108.35 $23.82
5. Waters Corporation $365.36 83 $37.29 B 20.92% 8.04% $414.15 / $275.05 $43.01
6. Natera, Inc. $215.31 $31.25 B -15.84% -15.13% $256.36 / $131.81 $12.26
7. IQVIA Holdings Inc. $183.45 22.11 $30.62 B 10.59% 22.46% $247.05 / $146.44 $38.34

Quarterly Results

Figures shown in M / B

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Sales148.45 M151.67 M156.81 M149.95 M183.64 M
Operating Profit-38.32 M-53.52 M-59.98 M-67.17 M-33.14 M
Net Profit-31.26 M21.63 M-148.44 M-67.61 M14.03 M
EPS in Rs-0.040.03-0.2-0.090.02

Profit & Loss

Figures shown in M / B

2025202420232022
Sales606.88 M713.14 M863.5 M1 B
Operating Profit-218.99 M-273.56 M-158.06 M-246.12 M
Net Profit-225.68 M-53.22 M-188.86 M-328.4 M
EPS in Rs-0.3-0.07-0.25-0.43

Balance Sheet

Figures shown in M / B

2025202420232022
Total Assets1.93 B2.2 B2.01 B2.17 B
Total Liabilities663.99 M834.76 M622.48 M605.61 M
Equity1.27 B1.37 B1.39 B1.56 B
Current Assets581.88 M662.09 M309.48 M394.52 M
Current Liabilities146.68 M193.1 M200.05 M213.48 M

Cash Flow

Last available yearly cash flow history

2025202420232022
Operating CF-178.54 M-183.49 M-28.2 M-95.19 M
Investing CF230.3 M352.21 M-18.2 M91.04 M
Financing CF-118.06 M184.17 M-11.3 M22.97 M
Free CF-190.82 M-208.5 M-44.47 M-119.77 M
Capex-12.28 M-25.01 M-16.27 M-24.58 M

5Y Margin & Growth History

Last 5 years of annual financial statement data.

2024202320222021
Revenue Growth %-17.41%-14.01%
Earnings Growth %71.82%42.49%
Profit Margin %-7.46%-21.87%-32.7%
Operating Margin %-38.36%-18.3%-24.51%
Gross Margin %30.64%36.84%28.7%
EBITDA Margin %18.97%-7.59%-26.97%

Dividend & Split History

Latest dividend payments and stock split events.

Dividend History

No dividend history available.

Stock Splits

No stock split history available.

Shareholding Pattern

Shares and value shown in M / B

Holder Name Type Shares Value % Out Report Date
Fidelity Concord Street Trust-Fidelity Extended Market Index Fund Mutual Fund 2.26 M $2.58 M 0% 2026-02-28
iShares Trust-iShares Russell 2000 ETF Mutual Fund 9.79 M $11.16 M 0.01% 2026-01-31
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund Mutual Fund 4.01 M $4.57 M 0.01% 2026-01-31
iShares Trust-iShares Russell 2000 Value ETF Mutual Fund 3.43 M $3.91 M 0% 2026-01-31
iShares Trust-iShares Biotechnology ETF Mutual Fund 2.89 M $3.29 M 0% 2026-01-31
Rubric Capital Management LP Institutional 47.79 M $54.48 M 0.06% 2025-12-31
Blackrock Inc. Institutional 34.85 M $39.73 M 0.05% 2025-12-31
Vanguard Group Inc Institutional 32.46 M $37 M 0.04% 2025-12-31
Geode Capital Management, LLC Institutional 11.06 M $12.61 M 0.01% 2025-12-31
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund Mutual Fund 9.43 M $10.75 M 0.01% 2025-12-31
State Street Corporation Institutional 8.95 M $10.21 M 0.01% 2025-12-31
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund Mutual Fund 6.98 M $7.96 M 0.01% 2025-12-31
Goldman Sachs Group Inc Institutional 5.99 M $6.83 M 0.01% 2025-12-31
UBS Group AG Institutional 5.35 M $6.1 M 0.01% 2025-12-31
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund Mutual Fund 4.7 M $5.36 M 0.01% 2025-12-31

Frequently Asked Questions — OPKO Health, Inc.

Will OPKO Health, Inc. stock hit $2 in 2026?

OPKO Health, Inc. (OPK) is currently trading at $1.44, with a 52-week range of $0.98 to $1.6. Reaching the $2 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.

Wall Street analysts currently have a consensus price target of $3.4 for OPKO Health, Inc., with a None rating, and the most bullish analysts see the stock reaching as high as $8.5. Whether OPKO Health, Inc. can reach $2 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.

Historically, OPK has delivered a -21.6% CAGR over the past 5 years, which suggests the stock has demonstrated meaningful long-term growth momentum. However, past performance does not guarantee future results, and short-term price movements can be influenced by macroeconomic shifts, interest rate changes, and investor sentiment. Use the OPK Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.

Is OPKO Health, Inc. stock worth buying at $1.44?

Whether OPKO Health, Inc. (OPK) is worth buying at $1.44 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:

Valuation: Valuation data is currently limited — check the full ratios section on StockSifting for the latest P/E, P/B, and EV/EBITDA figures.

Profitability & efficiency: OPKO Health, Inc. has a Return on Capital Employed (ROCE) of -12.3%, which reflects modest capital efficiency. Its Return on Equity (ROE) stands at -16.7%.

Financial health: The Debt-to-Equity ratio of 31.29 indicates a higher degree of financial leverage — investors should monitor debt servicing capacity.

Analyst view: The Wall Street consensus recommendation for OPK is currently None, with a mean price target of $3.4 based on 6 analyst ratings. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.

What is the analyst price target for OPKO Health, Inc. (OPK) in 2026?

As of 2026, Wall Street analysts have set a consensus (mean) price target of $3.4 for OPKO Health, Inc. (OPK), aggregated from 6 analyst ratings. The overall analyst recommendation is None.

The price target range spans from $1.4 on the bearish end to $8.5 on the most optimistic projection, with a median target of $3.0. This wide range reflects differing views on OPKO Health, Inc.'s growth prospects, competitive positioning, and macroeconomic sensitivity.

It is important to note that analyst price targets are forward-looking estimates based on financial models, earnings projections, and sector assumptions — they are not guarantees. Targets are regularly revised following quarterly earnings results, management guidance updates, or shifts in the broader economic outlook. Stocks can trade significantly above or below analyst targets depending on market conditions. View the full analyst breakdown and track target revisions on the OPK analysis page on StockSifting.

What will OPKO Health, Inc. stock be worth in 2029?

Projecting OPKO Health, Inc. (OPK)'s stock price 3 years into the future — to 2029 — requires making assumptions about the company's earnings growth, valuation multiple, and broader market conditions. No projection is guaranteed, but historical growth rates offer a reasonable starting point.

Based on OPK's historical 5-year Compound Annual Growth Rate (CAGR) of -21.6%, if that rate of growth were to continue, the stock could reach approximately $1 by 2029 — up from its current price of $1.44. This projection assumes the historical CAGR holds, which depends on OPKO Health, Inc. sustaining its revenue growth, maintaining profit margins, and the market continuing to reward it at a similar valuation multiple.

In reality, stock prices rarely follow a straight-line trajectory. Short-term volatility, earnings misses, sector rotations, interest rate changes, and macroeconomic events can all cause significant deviations from any modeled path. Investors with a 3-year horizon should focus on the fundamental business trajectory — revenue growth, expanding margins, and free cash flow generation — rather than short-term price fluctuations.

You can model different scenarios — conservative, base, and bull case — using the OPK Return Calculator on StockSifting. Enter any investment amount and CAGR assumption to see projected outcomes over your chosen time horizon. All projections are mathematical estimates only and do not constitute financial advice.